

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A muco-adhesive solid therapeutic composition containing an active ingredient that is a mixture of extracts obtained from the plant species *Sambucus nigra*, *Centella asiatica* and *Echinacea purpurea*, and excipients, said excipients comprising a bulk ingredient, an adhesive polymer of acrylic acid and polyvinylpyrrolidone; wherein the muco-adhesive solid therapeutic composition adheres to mucosal tissue.
2. (Previously Presented) A muco-adhesive solid therapeutic composition according to claim 1 provided in the form of a tablet, wherein the surface of said tablet is partially coated with a non-adhesive material, such that said tablet is provided with a first, adhesive side and a second, coated, non-adhesive side.
3. (Previously Presented) A muco-adhesive solid therapeutic composition according to claim 1, comprising the active ingredient in an amount from 5 to 15 percent, lactose in an amount from 50 to 65 percent, an adhesive polymer of acrylic acid in an amount from 10 to 20 percent, and polyvinylpyrrolidone in an amount from 10 to 20 percent, or a mixture thereof, based on the total weight of the composition.
4. (Canceled)
5. (Previously Presented) A muco-adhesive solid therapeutic composition according to claim 1 further comprising hydroxypropyl cellulose.
6. (Previously Presented) A muco-adhesive solid therapeutic composition according to claim 2 further comprising hydroxypropyl cellulose.

7. (Previously Presented) A muco-adhesive solid therapeutic composition according to claim 3 further comprising hydroxypropyl cellulose.

8. (Previously Presented) A muco-adhesive solid composition according to claim 1, wherein the muco-adhesive solid composition is structurally suitable for buccal administration.

9. (Previously Presented) A muco-adhesive solid composition according to claim 1, wherein the muco-adhesive solid composition is structurally suitable for vaginal administration.

10. (Previously Presented) A muco-adhesive solid composition according to claim 1, wherein the muco-adhesive solid composition is structurally suitable for anal administration.

11. (Previously Presented) A method of treating a mucosal tissue in a patient comprising the step of: contacting a mucosal tissue lesion with a therapeutically effective amount of a muco-adhesive solid therapeutic composition containing an active ingredient that is a mixture of extracts obtained from the plant species *Sambucus nigra*, *Centella asiatica* and *Echinacea purpurea*, and excipients, said excipients comprising a bulk ingredient, an adhesive polymer of acrylic acid and polyvinylpyrrolidone.

12. (Previously Presented) A method according to claim 11, wherein said mucosal tissue is selected from the group consisting of buccal mucosal tissue, vaginal mucosal tissue, and anal mucosal tissue.

13. (Currently Amended) A method according to claim 11, wherein said muco-adhesive composition is provided in the form of a tablet, and wherein a surface of the tablet is partially coated with a non-adhesive material, such that said tablet is provided with a first, adhesive side and a second, coated, non-adhesive side,

14. (Previously Presented) A method according to claim 13 comprising contacting the first, adhesive side of the tablet with the mucosal tissue lesion, such that the coated non-adhesive side projects away from said lesion.

15. (Previously Presented) A method according to claim 13, wherein an amount of said *Sambucus nigra* extract ranges between about 0.05 mg to about 15 mg, wherein an amount of said *Centella asiatica* extract ranges between about 0.05 mg to about 15 mg, and wherein an amount of said *Echinacea purpurea* extract ranges between about 0.05 mg to about 15 mg.

16. (Previously Presented) A method according to claim 11, wherein the step of contacting occurs for a period of time ranging between about 1 hour and about 5 hours.